ShopSpell

The Organic Chemistry of Drug Synthesis [Hardcover]

$372.99     $381.75    2% Off      (Free Shipping)
100 available
  • Category: Books (Medical)
  • Author:  Lednicer, Daniel, Mitscher, Lester A.
  • Author:  Lednicer, Daniel, Mitscher, Lester A.
  • ISBN-10:  0471855480
  • ISBN-10:  0471855480
  • ISBN-13:  9780471855484
  • ISBN-13:  9780471855484
  • Publisher:  Wiley-Interscience
  • Publisher:  Wiley-Interscience
  • Pages:  272
  • Pages:  272
  • Binding:  Hardcover
  • Binding:  Hardcover
  • Pub Date:  01-May-1991
  • Pub Date:  01-May-1991
  • SKU:  0471855480-11-MPOD
  • SKU:  0471855480-11-MPOD
  • Item ID: 100915421
  • List Price: $381.75
  • Seller: ShopSpell
  • Ships in: 2 business days
  • Transit time: Up to 5 business days
  • Delivery by: Jan 20 to Jan 22
  • Notes: Brand New Book. Order Now.
Updated every five years, the series represents the optimal compromise between currency and a sufficient body of material for cohesive and comprehensive treatment in a monograph. Provides a quick yet thorough overview of the synthetic routines that have been used to access specific classes of therapeutic agents. Materials are organized by chemical class, and syntheses are taken back to available starting materials. Discusses disease state, rational for method of drug therapy, biological activities of each compound and preparation. Coverage also includes those generic pharmaceutical compounds not accorded clinical status. A glossary defines biological terms.Aliphatic and Alicyclic Compounds.

Monocyclic Aromatic Compounds.

Polycyclic Aromatic Compounds and Their Reduction Products.

Steroids.

Five-Membered Ring Heterocycles.

Six-Membered Ring Heterocycles.

Five-Membered Ring Benzofused Heterocycles.

Six-Membered Ring Benzofused Heterocycles.

Bicyclic Fused Heterocycles.

beta-Lactam Antibiotics.

Miscellaneous Heterocycles.

Indexes.Daniel Lednicer, PhD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.

Lester A. Mitscher, Ph.D., recognized for his research achievements by numerous institutions, serves as a consultant for the Nală%

Add Review